Use of PEG-rHuMGDF in platelet angraftment after autologous stem cell transplantation

Bone Marrow Transplantation

Volumn 26, Issue 10, 2000, Pages 1083-1088

  Fields, K K ^a   Crump, M ^b   Bence Bruckler, I ^c   Bernstein, S ^d   Williams, S ^e   Frankel, S ^f   Miller, A ^g   Demetri, G ^h   Nabholtz, J M ⁱ   Cruickshank, S ^j   Lill, M ^k  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^g TULANE UNIVERSITY MEDICAL CENTER   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ CROSS CANCER INSTITUTE   (Canada)

^j AMGEN INC   (United States)

^k CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

Clinical trial; Engraftment; PEG rHuMGDF; Platelet; Transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; HEPARIN; LIGAND; MACROGOL DERIVATIVE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; TICLOPIDINE; WARFARIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER MORTALITY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FATIGUE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MALE; NAUSEA; NEUTROPENIA; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; VOMITING;

EID: 0033709243     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702662     Document Type: Article

References (21)

1. An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation
2. Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: An unresolved problem and possible approaches to resolve it
3. Febrile reactions after platelet transfusion: The effect of single vs multiple donors
4. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusion
5. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
6. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl
7. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production
8. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo
9. Stimulation of megakaryocytopoiesis by the c-Mpl ligand
10. Purification and characterization of thrombopoietin
11. Megakaryocyte growth and development factor: Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia
12. Promotion of megakaryocyte progenitor expansion and differentiation by the c-MpI ligand thrombopoietin
13. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates
14. Biology of thrombopoiesis and the role of Mpl ligand in the production and function of platelets
15. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer
16. Effects of polyethylene glycol recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer
17. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer
18. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients
19. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy
20. Predictive factors for peripheral-blood progenitor cell collections using a single large-volume leukapheresis after cyclophosphamide and G-CSF mobilisation
21. Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts